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as a non-prescription drug in all but two states. The purpose of this project was to
assess the relationship between PSE sales and indicators of methamphetamine
supply, specifically the number of clandestine laboratory incidents reported, in
Kentucky. METHODS: We calculate regression models predicting clandestine
methamphetamine lab incidents using 2010 county level Kentucky data. Explana-
tory factors include PSE sales (in grams), methamphetamine-related hospitaliza-
tions, USDA urban/rural indicator, methamphetamine related arrest, controlled
substance (CS) prescriptions dispensed, and population. Data sources include the
Kentucky All Schedule Prescription Electronic Reporting Program, the Kentucky
Inpatient Discharge Data Set, the Kentucky State Policy Crime in Kentucky Report,
and Clandestine Laboratory Surveillance System. RESULTS: Results indicate a
strong relationship between PSE sales and clandestine labs (p.001). Population
has a negative relationship to labs, with larger counties less likely to have clandes-
tine labs (P.002). Methamphetamine related hospitalizations have a positive re-
lationship to labs (P .001). Methamphetamine related arrests have a negative
relationship to labs (P .05).CONCLUSIONS: PSE sales have a strong relationship to
clandestine labs, with greater sales of PSE leading to a greater number of clandes-
tine labs. Our findings have important policy implications as states struggle with
policy options to reducemethamphetamine abuse. Tighter restrictions on PSEmay
be justified as a means to reduce clandestine methamphetamine labs.
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OBJECTIVES: The Drug Safety and Effectiveness Network (DSEN) in Canada was
created in response formore evidence on ‘real world’ drug safety and effectiveness
in the post-market phase. The goal of the Network Meta-Analysis (NMA) Collabor-
ative was to establish within DSEN an innovative partnership of health methodol-
ogists with four distinct yet complementary areas of expertise relevant to network
meta-analysis (biostatistics, safety/effectiveness systematic reviews, health eco-
nomics, and knowledge translation) and closely linked with international experts
and partner organizations such as ISPOR that are actively involved in health
research. METHODS: A proposal was developed and submitted to the Canadian
Institutes of Health Research (CIHR) for establishing a Collaborative for providing
rapid response to specific queries by utilizing network meta-analysis and safety
and effectiveness systematic reviews; providing a proactive platform for the devel-
opment and application of innovative, sophisticated, leading edge analyticalmeth-
ods for NMA and safety and effectiveness systematic reviews; developing knowl-
edge translation strategies that fill gaps in knowledge required by end-users to
make evidence-based decisions about drug safety and effectiveness that are based
on NMAs; establishing practical and interactive training and mentorship opportu-
nities for trainees through international links with partners specializing in drug
safety and effectiveness research. RESULTS: The proposal was peer-reviewed at
CIHR for responding to safety and effectiveness using NMA, developing innovative
NMA techniques, translating knowledge and building capacity. The proposal was
successful and funding was allocated. The demonstration project awarded was
evaluating neworal anti-coagulants compared towarfarin or lowmolecularweight
heparin in preventing stroke and other cardiovascular events in patientswith atrial
fibrillation. CONCLUSIONS: The infrastructure for the Collaborative will permit
safety and effectiveness reviews involving NMA to be conducted and innovative
methods developed. The first review completed on new oral anti-coagulants incor-
poratingNMAprovided informative comparisons between the anticoagulants from
both a therapeutic and economic perspective.
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OBJECTIVES: To test amore uniformly structured approach to evaluating evidence
for formulary decision making among managed care decision makers.METHODS:
A structured framework assessing the impact of costs, efficacy benefits, safety
concerns, and certainty of efficacy and safety evidence on formulary access was
tested using four hypothetical clinical conditions (breast cancer, osteoporosis, Alz-
heimer’s disease, and hypertension). After recruitment from a convenience sam-
ple, respondents were assigned via balanced incomplete block design to rate 12
scenarios per clinical condition on a 1-9 scale (1no access, 9 open access). Dis-
tribution of ratings, means, medians, and rate of disagreement was calculated.
Mixed effects linear regression models using maximum likelihood, with rater as a
random effect, were fit to estimate the association of clinical condition, cost, effi-
cacy certainty, safety certainty, efficacy benefit, and safety concerns with level of
formulary access. RESULTS: Seventy-nine P&T decision-makers completed the
survey between February-October 2011 resulting in 3783 evaluable responses
(2823pharmacy directors, 960medical directors). Mean ratings were lower
among pharmacy directors vs. medical directors (3.92 vs. 4.36, p0.093). Adjusted
formulary access ratings differed by clinical condition (breast cancer 4.40; osteo-
porosis 4.04; Alzheimer’s 4.00, and hypertension 3.70). Individual raters had sub-
stantial disagreement in individual scenario ratings (MAD 0.25-2.19). Across all
conditions, greater formulary access was significantly associated with greater cer-
tainty of safety evidence (high vs. low 1.60), greater certainty of efficacy evidence
(0.72), greater magnitude of efficacy benefit (0.43), fewer safety concerns (0.22) and
lower comparative cost (0.54). CONCLUSIONS: Greater formulary access was asso-
ciated with greater efficacy benefit, certainty of efficacy and safety evidence, lower
costs, and fewer safety concerns. Despite substantial inter-rater variation within
each scenario, the structure of the framework held during testing with a broad
number of P&T decision-makers, suggesting a more structured approach may re-
sult in greater clarity and transparency in formulary decision-making.
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OBJECTIVES: To evaluate medication adherence and persistence in patients with
acute coronary syndromes (ACS) who initiated prasugrel following a percutaneous
coronary intervention (PCI).METHODS:We identified adult patients with no prior
stroke/transient ischemic attack who filled prasugrel as their first dispensed out-
patient thienopyridine within 30 days post ACS-PCI discharge from July 10, 2009 to
June 30, 2010 using claims from the Thomson ReutersMarketscan dataset. Baseline
characteristics were assessed in the 6 months prior to the index hospitalization,
and patients were required to have 12 months of continuous enrollment post-
discharge. Predictors of adherence 80%, calculated using the medication posses-
sion ratio (MPR) during the 12-month follow-up period, were identified using a
logistic regression model. Persistence was assessed with survival analysis tech-
niques using a15-day gap to define a discontinuation. ACoxproportional hazards
model identified predictors of prasugrel discontinuation. RESULTS:The cohortwas
composed of 1340 patients with a mean age of 56.3 years; 79.5% were male. The
average MPR was 0.79 and nearly 70% of patients had adherence 80%. Patients
with prior statin use had higher odds of adherence (OR: 1.59, 95% CI: 1.22-2.09).
Coagulation defects (OR: 0.13, 95% CI: 0.03-0.52), baseline depression (OR: 0.33, 95%
CI: 0.14-0.75), history of bleeding (OR: 0.44, 95%CI: 0.20-0.95), prior PCI (OR: 0.61, 95%
CI: 0.39-0.94), and prior clopidogrel use (OR: 0.68, 95% CI: 0.46-1.00) were associated
with decreased odds of adherence. The median time to prasugrel discontinuation
was 242 days. Baseline factors associated with prasugrel discontinuation were
prior anemia (HR: 1.65, 95% CI: 1.21-2.25), prior cardiomyopathy (HR: 2.07, 95% CI:
1.02-4.19), and prior deep vein thrombosis (HR: 2.71, 95% CI: 1.00-7.32).
CONCLUSIONS: Adherence to prasugrel following ACS-PCI was relatively high. Pa-
tients with coagulation defects or depression at baseline had the highest odds of
suboptimal adherence. Anemia, prior DVT and cardiomyopathy were among fac-
tors associated with prasugrel early discontinuation.
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OBJECTIVES: Adherence comparisons of biologic agents used to treat Crohn’s dis-
ease (CD) have typically compared adherent and non-adherent patients. Non-ad-
herence may be due to efficacy, tolerability, lack of follow-up or patient-centered
reasons. There is a need for a more in-depth examination of non-adherence. Pur-
pose was to compare healthcare costs of CD patients who were adherent vs. inter-
mittently adherent on infliximab (IFX) therapy.METHODS: Patients with1 claims
for IFX initiated between 1/1/2006-12/31/2009 who had 2 diagnoses of CD (ICD-9-
CM: 555.XX) during the pre-index period were identified from Thomson Reuters
Marketscan®Databases. Patients had to be18 years, continuously enrolled for 12
months before and after IFX initiation, and had no prior use of IFX during 360-days
pre-index. Patients with prior biologic therapy or rheumatoid arthritis (ICD-9-CM:
714.XX) were excluded. Adherent group was classified as having amedication pos-
session ratio (MPR) of 80%; intermittently adherent group had an MPR80% with
IFX claims spanning 90% or more of the observation period. Differences between
the adherent and intermittently adherent groups were assessed using propensity-
weighted general linear models. RESULTS: A total of 599 CD patients were identi-
fied (360 adherent; 239 intermittently adherent) with a mean (SD) age of 42.9 (15.5)
and 50.9% were female. Propensity-weighted mean total healthcare costs exclud-
ing IFX were $13,097 vs. $20,068 (P0.0001) for the adherent vs. intermittently
adherent groups. Mean all-cause component costs were $2,764 vs. $6,665 (P0.001)
for hospitalizations, and $7,074 vs. $10,196 (P0.0001) for outpatient visits among
the adherent vs. intermittently adherent groups, respectively; no significant cost
differences were observed in ER visits, other prescription or total costs (component
 IFX). CONCLUSIONS:Adherencewas associatedwith lower total non-IFX health-
care costs. Comparison of adherent vs. intermittently adherent patients may pro-
vide a conservative test of the effect of adherence since patients that were inter-
mittently adherent have some IFX exposure.
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